Trailblazer: Global study to investigate safety and efficacy of Donanemab in early symptomatic Alzheimer’s disease. Aged 60-85 years, MMSE 20-28, roughly 93 weeks of trial related activities.
Trailrunner: A study of Remternetug verus placebo in early Alzheimer’s Disease participants at risk for cognitive and functional decline. Aged 65-80 years, MMSE >26, up to 100 weeks of trial related activities.
SELENATE: A phase 2b Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probable Behavioural Variant Fronto-temporal Dementia. Aged >35 years, 1 year of trial related activities.
Cares-X/ Kinoxis: A Multi-centre, Phase 2a, Double-blind, Placebo-controlled, Randomised Study to Examine the Safety, Tolerability, and Efficacy of KNX100 in the Treatment of Subjects with Agitation Associated with Dementia. Aged 50-90 years, MMSE 10-24, 10 weeks of trial related activities.
NAVAIDD Study: Neurofilament light chain And Voice Acoustics In Dementia Diagnosis. A cohort study to assess the diagnostic utility of plasma neurofilament light chain in all cause dementia. This study is including anyone attending Eastern health with a cognitive complaint.
Click on the video for more information.
Click on a link below to view this video in your language.